SlideShare ist ein Scribd-Unternehmen logo
1 von 47
Primary Hypertension
   2. Pathophysiology


   Prof. Dr. med. Günter Hennersdorf
                Germany
       SES consultant cardiologist
Pathophysiology of Hypertension

• Primary Hypertension 90%
      – Prevalence about 60% (age 60+)
      – Prevalence about 15-25% (age 25+)
      – Prevalence mean 35%
• Secondary Hypertension 10%
      – but: may normalize by special treatment (surgery,
        hormone treatment)!



April 2013             ghennersdorf SES FESC DGK
Pathophysiology of Hypertension



                   Primary Hypertension
             H. without primary organic cause




April 2013              ghennersdorf SES FESC DGK
Pathophysiology of Hypertension
                        Mean SBP
                                                              Female
                                                               Male




      Normal course
of blood pressure over age



                             Mean DBP        age



                                                             male
                                                             female


                                             age
 April 2013                      ghennersdorf SES FESC DGK
Cardiovascular risk factors
• not modifyable
      – Ethnic-genetic risk (black people)
      – Age
      – Gender
• modifyable
      –      Hypertension
      –      Hyperlipidemia (Cholesterol, TGs)
      –      Smoking
      –      Diabetes
      –      Overweight
      –      Inactivity (physical)
      –      Stress




April 2013                        ghennersdorf SES FESC DGK
Specific hypertension risks
• not modifyable
      – Ethnic-genetic risk (black people)
      – Age
      – Gender
• modifyable
      –      Diabetes
      –      Overweight
      –      Alcohol
      –      Salt intake
      –      combination



April 2013                 ghennersdorf SES FESC DGK
Prevalence of risk factors
             within western populations
             (FRAMINGHAM-Trial 1998):

             Hypertension                    20 %
                  >65 J.:                    65%

             Smoking                         31 %

             Overweight                      54 %

             Hyperlipidemia                  50 - 60 %

April 2013                  ghennersdorf SES FESC DGK
Pathophysiology of Hypertension: risks




             mortality risk and blood pressure
April 2013         ghennersdorf SES FESC DGK
Factors inducing Hypertension
•    Renin-angiotensin system RAS, RAAS
•    Sympathetic nervous system
•    Insuline resistance
•    Overweight
•    Stiff vessel walls (endothelial dysfunction)
•    Vasoactive substances (NO, Endotheline)
•    Kallikrein secretion
•    Natriuretic peptides

April 2013              ghennersdorf SES FESC DGK
Factors inducing Hypertension
• Neurohumoral system dysbalance
      – Renin-angiotensin system RAS, RAAS
      – Sympathetic nervous system




                Most important hypertension cause!




April 2013              ghennersdorf SES FESC DGK
Pathophysiology of Hypertension


Heart Rate      x   Stroke volume




      cardiac output                x   Peripheral resistance       =   Blood pressure


                                    Basic equation according to
                                    Law of OHM:

             Current I              x      Resistance R             =     Voltage U




April 2013                              ghennersdorf SES FESC DGK
Neuro-humoral Regulation of Hypertension

    Heart rate x stroke volume   x   Peripheral resistance        =     Blood pressure

                                        alpha1
               beta1




               Norepinephrine                    Angiotensin II




              Nervous system                   Humoral RAAS*

                                             *RAAS or RAS: renine angiotensine aldosterone system



April 2013                           ghennersdorf SES FESC DGK
Pathophysiology of Hypertension




             The role of endothelium
             and the RAAS cascade




April 2013         ghennersdorf SES FESC DGK
Pathophysiology of Hypertension
                                                        prorenine, katecholamines


                             Angiotensinogene
                                           Renin         Pathway of RAAS in the
Pathway of RAAS in the
Organism (kidney, heart,                                 Tissues: e.g.
                                Angiotensin I
Vessels) to maintain                                     Vessel wall
Fluid volume control,                       ACE
Adjustment of CO and
Resistance.                     Angiotensin II           Competition of receptors:
If regulation fails, high                                AT1 vasoconstriction
                                                         AT2 vasodilatation
blood pressure occurs


                                   receptor

                            AT1                AT2
April 2013                  ghennersdorf SES FESC DGK
Pathophysiology of Hypertension:
    Angiotensin II Stimulation
                                      Sodium, renine




                                       Kidney




                                       Ang II*         *Ang II effects mediated by AT1




                         Hypophysis                      Adrenal gland


                Hormone release                                      Aldosterone, katecholamines




   April 2013                         ghennersdorf SES FESC DGK
Pathophysiology of Hypertension:
     Angiotensin II Effects

                                                 synaptic conduction
                                     Brain

vasoconstriction


                     vessels         Ang II             Heart          hypertrophy



                     constriction




AT1 mediated effects of              Uterus      contraction
Angiotensin II

        April 2013                  ghennersdorf SES FESC DGK
Pathophysiology of Hypertension


                 basic structure and contents of the vessel intima
endothelium
                                                        Contents
                                                        Smooth muscle cells
intima            SMC                                   SMC
media                                                   Collagenes
                                                        Thrombocytes
Outer layer                                             Ox-LDL
                                                        NO
                                                        Kinines
                                                        Enzymes
                                                        coagulation factors
                                                        platelet activation factors
                                                        thromboxane
   April 2013                                           prostacycline
                                ghennersdorf SES FESC DGK
Pathophysiology of Hypertension
                                               ACh
    Vasoconstriction                                                        Vasodilatation

                               NE                               Vessel dilatation;
                          NE                                    endothelium intact
                    NE




                                               ACh

                               NE
NE=Norepinephine
Ach=Acetylcholine         NE

                    NE                                          no dilatation;
                                                                endothelium removed
  Furchgott‘s basic experiment (1980): key role of endothelium
   April 2013                       ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

                                  platelets




                 growth factors




Endothelial dysfunction causing atherosclerosis and vasoconstriction, infarction
    April 2013                          ghennersdorf SES FESC DGK
Angiotensin II Actions
                               on endothelium and
                                NO =nitric oxide




                       AT1                                   AT2

             AT1 stimulation                            AT2 stimulation
                  leads to:                                    leads to:
                  growth+
              vasoconstriction                              differentiation
                                                            vasodilatation
                                vasoactivity
       NO inhibition                                                    NO
                              Smooth muscle cell
                                   growth

April 2013                      ghennersdorf SES FESC DGK    modified acc. to Unger T et al 1996
Pathophysiology of Hypertension


                               constriction




                           vascular resistance



             Endothelial dysfunction causing hypertension
April 2013                 ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

               Heart rate x stroke volume   x    Peripheral resistance      =   Blood pressure




                              n.sympathicus                              RAAS*




                          Stress                 Genetic/Familial                      Vasoconstriction
                           social                    ethnic
                           familial                  Hereditary                             Endothelial
                                                     salt sensitivity                       dysfunction
*renine angiotensine aldosterone system

  April 2013                                    ghennersdorf SES FESC DGK
Pathophysiology of Hypertension



                   Conclusion:
                   Conclusion:
             Primary Hypertension
             Primary Hypertension
          is a target disease mainly
           is a target disease mainly
 of the RAAS -- intima -- endothelium system!
 of the RAAS intima endothelium system!

                   the endothelium is the major player


April 2013                 ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

                               time course of hypertension development
                 no symptoms             Nonspecific Symptoms:
                                             Head ache,
                                             Palpitation,
Onset,Trigger        Chronic stage           Exertional dyspnea   target organ damage     death




        3                  4                        5                      6            6+ (x10th years)




                                 accelerated course
   April 2013                        ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

              Trigger example: Obesity, Hyperinsulinism, Type-2-
                                  Diabetes


                                  Hypertension



                           Metabolic syndrome (X)




April 2013                    ghennersdorf SES FESC DGK
Pathophysiology of Hypertension


    Heart rate x stroke volume     x   Peripheral resistance       =      Blood pressure

                                                     AT2 -
        beta1                                                          + (NO )
                                                     AT1 +
                          alpha1
      Norepinephrine                       Angiotensin II               Hyperinsulinemia




        Sympathicus                             RAAS


April 2013                             ghennersdorf SES FESC DGK
Pathophysiology of Hypertension




April 2013             ghennersdorf SES FESC DGK
Pathophysiology of Hypertension



                    Target organ damage
                          followed by
                     arterial hypertension




April 2013              ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

   • Target organ damage:
         – Brain: Stroke (ischemic, hemorrhagic)
         – Heart: CAD, Heart failure (mainly diastolic)
         – Vessels:
              • Peripheral arterial disease
              • Central arterial disease: aortic dissection, aneurysm
              • Renovascular disease




April 2013                   ghennersdorf SES FESC DGK
Typical target organ damages following arterial hypertension

                           CAD


                                                        stroke




     LV hypertrophy




                           Peripheral artery disease:
                           necrosis, gangrene

April 2013                   ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

                       Left ventricular
                       hypertrophy
                       Coronary Atherosclerosis
                                                            Heart failure
                                                         (prevalence ~50%)

       Main target lesions

                                                            Brain: Stroke
                                                         (prevalence ~20%)
                        Wall damage
                        Cerebral Atherosclerosis


                                                         Renovascular damage


April 2013                   ghennersdorf SES FESC DGK
Pathophysiology of Hypertension




             Left ventricular hypertrophy      remodeling
             (w. anterior wall infarction)                      Heart failure



April 2013                          ghennersdorf SES FESC DGK
Heart failure and hypertension

             Diastolic Heart failure: stiffness and relaxation disturbances




u



             normal                     Early stage                   Late stage
                           Ultrasound appearance of mitral flow patterns (EA relation)


    April 2013                     ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

                   Survival rate in relation to renal damage (by renal albuminuria)




               Survival rate%                                            Alb. < median
                                                                         Alb. > median

                                                                         Median 7,52 µg/min
                                                                         P=0,0078




April 2013                         ghennersdorf SES FESC DGK
Pathophysiology of Hypertension



                Secondary Hypertension
              H. with primary organic cause




April 2013             ghennersdorf SES FESC DGK
Pathophysiology of Hypertension:
                                           secondary H.

             •   Renal 5%
                  –   Parenchymal
                  –   Renovascular (0,3%) (corrected to normal by balloon treatment or surgery!)
                  –   Tumors
                  –   Little‘s disease
             •   Endocrine
                  –   Thyroid dysfunction (1%)
                  –   Adrenal (0,3%)
                  –   Carcinoid
                  –   hormones
             •   Aortic coarctation
             •   Pregnancy
             •   Neurogenic (brain tumor, lead, porphyria, sleep apnea)
             •   Acute stress (including surgery)
             •   iv. volume increase
             •   Alcohol abuse

    Some may induce primary hypertension, so that the relationships sometimes are weak
April 2013                                ghennersdorf SES FESC DGK
Pathophysiology of Hypertension



            Systolic Hypertension
(H. of the aged w. or w/o. diastolic lowering




 April 2013             ghennersdorf SES FESC DGK
Pathophysiology of Hypertension: Isolated
                      systolic Hypertension (ISH).


      • Rigidity of the aorta (aged aorta)
      • Increased cardiac output
             – Aortic Valve regurgitation
             – AV fistula
             – Thyreotoxic crisis
             – Paget‘s disease (bone vessel fistulas)
             – Beriberi (Vit. B deficiency)
             – Hyperkinetic circulation (young, unfit)

April 2013                 ghennersdorf SES FESC DGK
Definition of arterial Hypertension AH*
                        systolic blood pressure      diastolic blood pressure

   Normal               <140                   and   <90
   (diabetic            <130                         <80)
   mild AH              140-179             and/or
                                                     90-104
   borderline AH        140-159                      90-94
   intermediate         >=180               and/or   >=105
   severe AH
   isolated             >=160                  and   <90
   systolic AH          140-159
   (ISH)
April 2013               ghennersdorf SES FESC DGK                  *WHO 2000
Pathophysiology of Hypertension:
                 Systolic Hypertension.




April 2013          ghennersdorf SES FESC DGK
Pathophysiology of Hypertension:
                 Systolic Hypertension.




April 2013          ghennersdorf SES FESC DGK
Pathophysiology of Hypertension:
                       Systolic Hypertension (SAH).

      • Risk of SAH in the elderly (SHEP, SYST-EUR Trials)

             – Stroke            20% Reduction)
             – Heart failure     54% Reduction)
             – Death             24%



             These results were maintained over 5 years observation




April 2013                     ghennersdorf SES FESC DGK
Pathophysiology of Hypertension: Morning
              Hypertension.



               Blood pressure

               Heart rate
               Resistance
               Cardiac output
               Renal function




April 2013    ghennersdorf SES FESC DGK
Increased cardiovascular morning risk
               Increased cardiovascular morning risk
                                                     Morning BP rise
             Stroke /2h
             Infarction /1 h




             6 pm                     0:00             6 am            12 am




April 2013                     ghennersdorf SES FESC DGK
Pathophysiology of Hypertension:
                          diastolic blood pressure DBP
                                                                       Prognosis
                 Stroke risk and DBP                       CAD risk and DBP

4,0                                       4,0

                                          2,0

1,0                                       1,0




           76   84   91   98 105                     76      84   91   98 105


  April 2013                   ghennersdorf SES FESC DGK
Pathophysiology of Hypertension

             understand
                          Save lives and improve life quality

                    diagnose



                                    treat




                                               control

April 2013                     ghennersdorf SES FESC DGK
Cardiovascular Diseases
    Hypertension Management
              part I
          The End

Weitere ähnliche Inhalte

Was ist angesagt?

Hypertension
HypertensionHypertension
HypertensionRahul B S
 
hypertension and cardiovascular disease
hypertension and cardiovascular diseasehypertension and cardiovascular disease
hypertension and cardiovascular diseaseAbhishek Agarwal
 
Hypertension (BLOOD PRESSURE)
Hypertension (BLOOD PRESSURE)Hypertension (BLOOD PRESSURE)
Hypertension (BLOOD PRESSURE)Muhammad Arsal
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failureNaser Tadvi
 
Essential Hypertension
Essential Hypertension Essential Hypertension
Essential Hypertension raheef
 
The Renin Angiotensin Andosterone System
The Renin Angiotensin Andosterone SystemThe Renin Angiotensin Andosterone System
The Renin Angiotensin Andosterone SystemDarya Daoud
 
Heart failure 2013 Pathophysiology
Heart failure 2013 PathophysiologyHeart failure 2013 Pathophysiology
Heart failure 2013 PathophysiologyGunter Hennersdorf
 
Treatment of Hypertension Treatment of Hypertension
Treatment of Hypertension 	 Treatment of HypertensionTreatment of Hypertension 	 Treatment of Hypertension
Treatment of Hypertension Treatment of HypertensionMedicineAndHealthCancer
 
Secondary hypertension
Secondary hypertensionSecondary hypertension
Secondary hypertensionraj kumar
 
Management of hypertensive crisis
Management of hypertensive crisisManagement of hypertensive crisis
Management of hypertensive crisisgelaye mandefro
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...MedicineAndFamily
 

Was ist angesagt? (20)

Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
hypertension and cardiovascular disease
hypertension and cardiovascular diseasehypertension and cardiovascular disease
hypertension and cardiovascular disease
 
Hypertension (BLOOD PRESSURE)
Hypertension (BLOOD PRESSURE)Hypertension (BLOOD PRESSURE)
Hypertension (BLOOD PRESSURE)
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failure
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 
heart Failure
heart Failureheart Failure
heart Failure
 
Hypertension
HypertensionHypertension
Hypertension
 
symptomatic hypertension
symptomatic hypertensionsymptomatic hypertension
symptomatic hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Essential Hypertension
Essential Hypertension Essential Hypertension
Essential Hypertension
 
The Renin Angiotensin Andosterone System
The Renin Angiotensin Andosterone SystemThe Renin Angiotensin Andosterone System
The Renin Angiotensin Andosterone System
 
Heart failure 2013 Pathophysiology
Heart failure 2013 PathophysiologyHeart failure 2013 Pathophysiology
Heart failure 2013 Pathophysiology
 
Treatment of Hypertension Treatment of Hypertension
Treatment of Hypertension 	 Treatment of HypertensionTreatment of Hypertension 	 Treatment of Hypertension
Treatment of Hypertension Treatment of Hypertension
 
Secondary hypertension work up
Secondary hypertension work upSecondary hypertension work up
Secondary hypertension work up
 
Secondary hypertension
Secondary hypertensionSecondary hypertension
Secondary hypertension
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Management of hypertensive crisis
Management of hypertensive crisisManagement of hypertensive crisis
Management of hypertensive crisis
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 

Ähnlich wie Pathophysiology of Primary Hypertension Risk Factors

TISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEMTISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEMRamachandra Barik
 
The renin angiotensin aldosterone system.
The renin angiotensin aldosterone system.The renin angiotensin aldosterone system.
The renin angiotensin aldosterone system.Ramachandra Barik
 
Hypertension 2013 Diagnostic Procedures
Hypertension 2013 Diagnostic ProceduresHypertension 2013 Diagnostic Procedures
Hypertension 2013 Diagnostic ProceduresGunter Hennersdorf
 
UPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTION
UPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTIONUPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTION
UPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTIONRamachandra Barik
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .pptImtiyaz60
 
Losocor co training south africa Dr Saurav deka
Losocor co training   south africa  Dr Saurav dekaLosocor co training   south africa  Dr Saurav deka
Losocor co training south africa Dr Saurav dekaassam1
 
Lect_Bloo_vesp.ppt
Lect_Bloo_vesp.pptLect_Bloo_vesp.ppt
Lect_Bloo_vesp.pptDiana321101
 
ARBs plus Calcium channel blockers in hypertension
ARBs plus Calcium channel blockers in hypertensionARBs plus Calcium channel blockers in hypertension
ARBs plus Calcium channel blockers in hypertensionMahmoud Yossof
 
ARNI in Heart Failure Management
ARNI in Heart Failure ManagementARNI in Heart Failure Management
ARNI in Heart Failure ManagementBibul2
 
DIANA@HEART FAILURE.pptx
DIANA@HEART FAILURE.pptxDIANA@HEART FAILURE.pptx
DIANA@HEART FAILURE.pptxAugustusCaesar7
 
Hypertensive Nephrosclerosis
Hypertensive NephrosclerosisHypertensive Nephrosclerosis
Hypertensive NephrosclerosisRandolph Tulsie
 
Management of Hypertension in Critical Illness
Management of Hypertension in Critical IllnessManagement of Hypertension in Critical Illness
Management of Hypertension in Critical IllnessDr.Mahmoud Abbas
 
The Relevance of Natriuretic Peptide in Medical Laboratory Diagnosis
The Relevance of Natriuretic Peptide in Medical Laboratory DiagnosisThe Relevance of Natriuretic Peptide in Medical Laboratory Diagnosis
The Relevance of Natriuretic Peptide in Medical Laboratory Diagnosisasclepiuspdfs
 

Ähnlich wie Pathophysiology of Primary Hypertension Risk Factors (20)

TISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEMTISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEM
 
The renin angiotensin aldosterone system.
The renin angiotensin aldosterone system.The renin angiotensin aldosterone system.
The renin angiotensin aldosterone system.
 
Hypertension 2013 Diagnostic Procedures
Hypertension 2013 Diagnostic ProceduresHypertension 2013 Diagnostic Procedures
Hypertension 2013 Diagnostic Procedures
 
UPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTION
UPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTIONUPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTION
UPDATES OF RENIN ANGIOTENSIN SYTEM INTERVENTION
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
 
Cardiorenal syndrome
Cardiorenal syndromeCardiorenal syndrome
Cardiorenal syndrome
 
Pathology of Hypertension
Pathology of HypertensionPathology of Hypertension
Pathology of Hypertension
 
Losocor co training south africa Dr Saurav deka
Losocor co training   south africa  Dr Saurav dekaLosocor co training   south africa  Dr Saurav deka
Losocor co training south africa Dr Saurav deka
 
Lect_Bloo_vesp.ppt
Lect_Bloo_vesp.pptLect_Bloo_vesp.ppt
Lect_Bloo_vesp.ppt
 
ARBs plus Calcium channel blockers in hypertension
ARBs plus Calcium channel blockers in hypertensionARBs plus Calcium channel blockers in hypertension
ARBs plus Calcium channel blockers in hypertension
 
Raas
RaasRaas
Raas
 
HYPERTENSION.pptx
HYPERTENSION.pptxHYPERTENSION.pptx
HYPERTENSION.pptx
 
ARNI in Heart Failure Management
ARNI in Heart Failure ManagementARNI in Heart Failure Management
ARNI in Heart Failure Management
 
Hypertension
HypertensionHypertension
Hypertension
 
DIANA@HEART FAILURE.pptx
DIANA@HEART FAILURE.pptxDIANA@HEART FAILURE.pptx
DIANA@HEART FAILURE.pptx
 
Hypertensive Nephrosclerosis
Hypertensive NephrosclerosisHypertensive Nephrosclerosis
Hypertensive Nephrosclerosis
 
Management of Hypertension in Critical Illness
Management of Hypertension in Critical IllnessManagement of Hypertension in Critical Illness
Management of Hypertension in Critical Illness
 
The Relevance of Natriuretic Peptide in Medical Laboratory Diagnosis
The Relevance of Natriuretic Peptide in Medical Laboratory DiagnosisThe Relevance of Natriuretic Peptide in Medical Laboratory Diagnosis
The Relevance of Natriuretic Peptide in Medical Laboratory Diagnosis
 
Htn
HtnHtn
Htn
 
Hypertension
HypertensionHypertension
Hypertension
 

Mehr von Gunter Hennersdorf

Mehr von Gunter Hennersdorf (11)

herzanatomie-pptx.pptx
herzanatomie-pptx.pptxherzanatomie-pptx.pptx
herzanatomie-pptx.pptx
 
HI-Herz.BIKE Saar
HI-Herz.BIKE SaarHI-Herz.BIKE Saar
HI-Herz.BIKE Saar
 
Herzbikesaar 2016 Endergebnisse
Herzbikesaar 2016 EndergebnisseHerzbikesaar 2016 Endergebnisse
Herzbikesaar 2016 Endergebnisse
 
HI-Herz.BIKE Saar
HI-Herz.BIKE SaarHI-Herz.BIKE Saar
HI-Herz.BIKE Saar
 
Bls2016b
Bls2016bBls2016b
Bls2016b
 
HI-Herz.BIKE Saar
HI-Herz.BIKE Saar HI-Herz.BIKE Saar
HI-Herz.BIKE Saar
 
Erste Ergebnisse des Herz.BIKE Saar-Projekts (erstes Halbjahr 2015)
Erste Ergebnisse des Herz.BIKE Saar-Projekts (erstes Halbjahr 2015)Erste Ergebnisse des Herz.BIKE Saar-Projekts (erstes Halbjahr 2015)
Erste Ergebnisse des Herz.BIKE Saar-Projekts (erstes Halbjahr 2015)
 
Präsentation Herz Bike Saar 04
Präsentation Herz Bike Saar 04Präsentation Herz Bike Saar 04
Präsentation Herz Bike Saar 04
 
Patientenvortrag Herzmuskelschwäche
Patientenvortrag HerzmuskelschwächePatientenvortrag Herzmuskelschwäche
Patientenvortrag Herzmuskelschwäche
 
Heart failure 2013 Therapy
Heart failure 2013 TherapyHeart failure 2013 Therapy
Heart failure 2013 Therapy
 
Heart failure 2013 Diagnostic Procedures
Heart failure 2013 Diagnostic ProceduresHeart failure 2013 Diagnostic Procedures
Heart failure 2013 Diagnostic Procedures
 

Kürzlich hochgeladen

ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 

Kürzlich hochgeladen (20)

ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 

Pathophysiology of Primary Hypertension Risk Factors

  • 1. Primary Hypertension 2. Pathophysiology Prof. Dr. med. Günter Hennersdorf Germany SES consultant cardiologist
  • 2. Pathophysiology of Hypertension • Primary Hypertension 90% – Prevalence about 60% (age 60+) – Prevalence about 15-25% (age 25+) – Prevalence mean 35% • Secondary Hypertension 10% – but: may normalize by special treatment (surgery, hormone treatment)! April 2013 ghennersdorf SES FESC DGK
  • 3. Pathophysiology of Hypertension Primary Hypertension H. without primary organic cause April 2013 ghennersdorf SES FESC DGK
  • 4. Pathophysiology of Hypertension Mean SBP Female Male Normal course of blood pressure over age Mean DBP age male female age April 2013 ghennersdorf SES FESC DGK
  • 5. Cardiovascular risk factors • not modifyable – Ethnic-genetic risk (black people) – Age – Gender • modifyable – Hypertension – Hyperlipidemia (Cholesterol, TGs) – Smoking – Diabetes – Overweight – Inactivity (physical) – Stress April 2013 ghennersdorf SES FESC DGK
  • 6. Specific hypertension risks • not modifyable – Ethnic-genetic risk (black people) – Age – Gender • modifyable – Diabetes – Overweight – Alcohol – Salt intake – combination April 2013 ghennersdorf SES FESC DGK
  • 7. Prevalence of risk factors within western populations (FRAMINGHAM-Trial 1998): Hypertension 20 % >65 J.: 65% Smoking 31 % Overweight 54 % Hyperlipidemia 50 - 60 % April 2013 ghennersdorf SES FESC DGK
  • 8. Pathophysiology of Hypertension: risks mortality risk and blood pressure April 2013 ghennersdorf SES FESC DGK
  • 9. Factors inducing Hypertension • Renin-angiotensin system RAS, RAAS • Sympathetic nervous system • Insuline resistance • Overweight • Stiff vessel walls (endothelial dysfunction) • Vasoactive substances (NO, Endotheline) • Kallikrein secretion • Natriuretic peptides April 2013 ghennersdorf SES FESC DGK
  • 10. Factors inducing Hypertension • Neurohumoral system dysbalance – Renin-angiotensin system RAS, RAAS – Sympathetic nervous system Most important hypertension cause! April 2013 ghennersdorf SES FESC DGK
  • 11. Pathophysiology of Hypertension Heart Rate x Stroke volume cardiac output x Peripheral resistance = Blood pressure Basic equation according to Law of OHM: Current I x Resistance R = Voltage U April 2013 ghennersdorf SES FESC DGK
  • 12. Neuro-humoral Regulation of Hypertension Heart rate x stroke volume x Peripheral resistance = Blood pressure alpha1 beta1 Norepinephrine Angiotensin II Nervous system Humoral RAAS* *RAAS or RAS: renine angiotensine aldosterone system April 2013 ghennersdorf SES FESC DGK
  • 13. Pathophysiology of Hypertension The role of endothelium and the RAAS cascade April 2013 ghennersdorf SES FESC DGK
  • 14. Pathophysiology of Hypertension prorenine, katecholamines Angiotensinogene Renin Pathway of RAAS in the Pathway of RAAS in the Organism (kidney, heart, Tissues: e.g. Angiotensin I Vessels) to maintain Vessel wall Fluid volume control, ACE Adjustment of CO and Resistance. Angiotensin II Competition of receptors: If regulation fails, high AT1 vasoconstriction AT2 vasodilatation blood pressure occurs receptor AT1 AT2 April 2013 ghennersdorf SES FESC DGK
  • 15. Pathophysiology of Hypertension: Angiotensin II Stimulation Sodium, renine Kidney Ang II* *Ang II effects mediated by AT1 Hypophysis Adrenal gland Hormone release Aldosterone, katecholamines April 2013 ghennersdorf SES FESC DGK
  • 16. Pathophysiology of Hypertension: Angiotensin II Effects synaptic conduction Brain vasoconstriction vessels Ang II Heart hypertrophy constriction AT1 mediated effects of Uterus contraction Angiotensin II April 2013 ghennersdorf SES FESC DGK
  • 17. Pathophysiology of Hypertension basic structure and contents of the vessel intima endothelium Contents Smooth muscle cells intima SMC SMC media Collagenes Thrombocytes Outer layer Ox-LDL NO Kinines Enzymes coagulation factors platelet activation factors thromboxane April 2013 prostacycline ghennersdorf SES FESC DGK
  • 18. Pathophysiology of Hypertension ACh Vasoconstriction Vasodilatation NE Vessel dilatation; NE endothelium intact NE ACh NE NE=Norepinephine Ach=Acetylcholine NE NE no dilatation; endothelium removed Furchgott‘s basic experiment (1980): key role of endothelium April 2013 ghennersdorf SES FESC DGK
  • 19. Pathophysiology of Hypertension platelets growth factors Endothelial dysfunction causing atherosclerosis and vasoconstriction, infarction April 2013 ghennersdorf SES FESC DGK
  • 20. Angiotensin II Actions on endothelium and NO =nitric oxide AT1 AT2 AT1 stimulation AT2 stimulation leads to: leads to: growth+ vasoconstriction differentiation vasodilatation vasoactivity NO inhibition NO Smooth muscle cell growth April 2013 ghennersdorf SES FESC DGK modified acc. to Unger T et al 1996
  • 21. Pathophysiology of Hypertension constriction vascular resistance Endothelial dysfunction causing hypertension April 2013 ghennersdorf SES FESC DGK
  • 22. Pathophysiology of Hypertension Heart rate x stroke volume x Peripheral resistance = Blood pressure n.sympathicus RAAS* Stress Genetic/Familial Vasoconstriction social ethnic familial Hereditary Endothelial salt sensitivity dysfunction *renine angiotensine aldosterone system April 2013 ghennersdorf SES FESC DGK
  • 23. Pathophysiology of Hypertension Conclusion: Conclusion: Primary Hypertension Primary Hypertension is a target disease mainly is a target disease mainly of the RAAS -- intima -- endothelium system! of the RAAS intima endothelium system! the endothelium is the major player April 2013 ghennersdorf SES FESC DGK
  • 24. Pathophysiology of Hypertension time course of hypertension development no symptoms Nonspecific Symptoms: Head ache, Palpitation, Onset,Trigger Chronic stage Exertional dyspnea target organ damage death 3 4 5 6 6+ (x10th years) accelerated course April 2013 ghennersdorf SES FESC DGK
  • 25. Pathophysiology of Hypertension Trigger example: Obesity, Hyperinsulinism, Type-2- Diabetes Hypertension Metabolic syndrome (X) April 2013 ghennersdorf SES FESC DGK
  • 26. Pathophysiology of Hypertension Heart rate x stroke volume x Peripheral resistance = Blood pressure AT2 - beta1 + (NO ) AT1 + alpha1 Norepinephrine Angiotensin II Hyperinsulinemia Sympathicus RAAS April 2013 ghennersdorf SES FESC DGK
  • 27. Pathophysiology of Hypertension April 2013 ghennersdorf SES FESC DGK
  • 28. Pathophysiology of Hypertension Target organ damage followed by arterial hypertension April 2013 ghennersdorf SES FESC DGK
  • 29. Pathophysiology of Hypertension • Target organ damage: – Brain: Stroke (ischemic, hemorrhagic) – Heart: CAD, Heart failure (mainly diastolic) – Vessels: • Peripheral arterial disease • Central arterial disease: aortic dissection, aneurysm • Renovascular disease April 2013 ghennersdorf SES FESC DGK
  • 30. Typical target organ damages following arterial hypertension CAD stroke LV hypertrophy Peripheral artery disease: necrosis, gangrene April 2013 ghennersdorf SES FESC DGK
  • 31. Pathophysiology of Hypertension Left ventricular hypertrophy Coronary Atherosclerosis Heart failure (prevalence ~50%) Main target lesions Brain: Stroke (prevalence ~20%) Wall damage Cerebral Atherosclerosis Renovascular damage April 2013 ghennersdorf SES FESC DGK
  • 32. Pathophysiology of Hypertension Left ventricular hypertrophy remodeling (w. anterior wall infarction) Heart failure April 2013 ghennersdorf SES FESC DGK
  • 33. Heart failure and hypertension Diastolic Heart failure: stiffness and relaxation disturbances u normal Early stage Late stage Ultrasound appearance of mitral flow patterns (EA relation) April 2013 ghennersdorf SES FESC DGK
  • 34. Pathophysiology of Hypertension Survival rate in relation to renal damage (by renal albuminuria) Survival rate% Alb. < median Alb. > median Median 7,52 µg/min P=0,0078 April 2013 ghennersdorf SES FESC DGK
  • 35. Pathophysiology of Hypertension Secondary Hypertension H. with primary organic cause April 2013 ghennersdorf SES FESC DGK
  • 36. Pathophysiology of Hypertension: secondary H. • Renal 5% – Parenchymal – Renovascular (0,3%) (corrected to normal by balloon treatment or surgery!) – Tumors – Little‘s disease • Endocrine – Thyroid dysfunction (1%) – Adrenal (0,3%) – Carcinoid – hormones • Aortic coarctation • Pregnancy • Neurogenic (brain tumor, lead, porphyria, sleep apnea) • Acute stress (including surgery) • iv. volume increase • Alcohol abuse Some may induce primary hypertension, so that the relationships sometimes are weak April 2013 ghennersdorf SES FESC DGK
  • 37. Pathophysiology of Hypertension Systolic Hypertension (H. of the aged w. or w/o. diastolic lowering April 2013 ghennersdorf SES FESC DGK
  • 38. Pathophysiology of Hypertension: Isolated systolic Hypertension (ISH). • Rigidity of the aorta (aged aorta) • Increased cardiac output – Aortic Valve regurgitation – AV fistula – Thyreotoxic crisis – Paget‘s disease (bone vessel fistulas) – Beriberi (Vit. B deficiency) – Hyperkinetic circulation (young, unfit) April 2013 ghennersdorf SES FESC DGK
  • 39. Definition of arterial Hypertension AH* systolic blood pressure diastolic blood pressure Normal <140 and <90 (diabetic <130 <80) mild AH 140-179 and/or 90-104 borderline AH 140-159 90-94 intermediate >=180 and/or >=105 severe AH isolated >=160 and <90 systolic AH 140-159 (ISH) April 2013 ghennersdorf SES FESC DGK *WHO 2000
  • 40. Pathophysiology of Hypertension: Systolic Hypertension. April 2013 ghennersdorf SES FESC DGK
  • 41. Pathophysiology of Hypertension: Systolic Hypertension. April 2013 ghennersdorf SES FESC DGK
  • 42. Pathophysiology of Hypertension: Systolic Hypertension (SAH). • Risk of SAH in the elderly (SHEP, SYST-EUR Trials) – Stroke 20% Reduction) – Heart failure 54% Reduction) – Death 24% These results were maintained over 5 years observation April 2013 ghennersdorf SES FESC DGK
  • 43. Pathophysiology of Hypertension: Morning Hypertension. Blood pressure Heart rate Resistance Cardiac output Renal function April 2013 ghennersdorf SES FESC DGK
  • 44. Increased cardiovascular morning risk Increased cardiovascular morning risk Morning BP rise Stroke /2h Infarction /1 h 6 pm 0:00 6 am 12 am April 2013 ghennersdorf SES FESC DGK
  • 45. Pathophysiology of Hypertension: diastolic blood pressure DBP Prognosis Stroke risk and DBP CAD risk and DBP 4,0 4,0 2,0 1,0 1,0 76 84 91 98 105 76 84 91 98 105 April 2013 ghennersdorf SES FESC DGK
  • 46. Pathophysiology of Hypertension understand Save lives and improve life quality diagnose treat control April 2013 ghennersdorf SES FESC DGK
  • 47. Cardiovascular Diseases Hypertension Management part I The End